American Society of Hematology

Fig. 2.

$Fig. 2. Prostratin induces proliferation of the nonadherent cellular fraction of human PBMCs. / Human PBMCs, 5 × 105 per well, were treated with a variety of mitogenic or proliferative agents including 10 μg/mL PHA, 50 IU/mL IL-2, PHA/IL-2, or 0.263 μM prostratin as indicated. No addition and DMSO served as control cultures. Proliferation of cells in all cultures peaked on day 6 after treatment. PHA/IL-2 treatment was most effective followed by PHA and IL-2, as single agents. Prostratin did not exhibit a significant proliferative effect. Each point represents the mean of 2 trials ± 1 SD. Cases where error bars are not clearly visible result from low SD, typically less than 1% in deviance.$

Prostratin induces proliferation of the nonadherent cellular fraction of human PBMCs.

Human PBMCs, 5 × 10⁵ per well, were treated with a variety of mitogenic or proliferative agents including 10 μg/mL PHA, 50 IU/mL IL-2, PHA/IL-2, or 0.263 μM prostratin as indicated. No addition and DMSO served as control cultures. Proliferation of cells in all cultures peaked on day 6 after treatment. PHA/IL-2 treatment was most effective followed by PHA and IL-2, as single agents. Prostratin did not exhibit a significant proliferative effect. Each point represents the mean of 2 trials ± 1 SD. Cases where error bars are not clearly visible result from low SD, typically less than 1% in deviance.

This Feature Is Available To Subscribers Only